PDF herunterladen
Thromb Haemost 1996; 75(06): 982
DOI: 10.1055/s-0038-1650412
Original Article
Schattauer GmbH Stuttgart

A Patient with Glanzmann Thrombasthenia and Epistaxis Successfully Treated with Recombinant Factor Vila

Lilian Tengborn
1   The Coagulation Centre, Department of Internal Medicine, Sweden
,
Bjorn Petrusson
2   ENT-Department, Sahlgrenska University Hospital, Goteborg, Sweden
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received: 06. Februar 1996

Accepted after revision14. März 1996

Publikationsdatum:
11. Juli 2018 (online)

Auch verfügbar auf
  als PDF herunterladen  Lizenzen und Reprints
 

  • References

  • 1 Petruson B. Epistaxis, a clinical study with special reference to fibrinolysis. Acta Otolaryngol 1974; (Suppl. 314) Suppl 34-36
    PubMedGoogle Scholar
  • 2 Rodgers RCP, Levin J. A critical reappraisal of the bleeding time. Seminars in Thromb Haemost 1990; 16: 1-20
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 3 Mannucci P, Vicente V, Vianello L, Cattaneo M, Alberca I. et al Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time. Blood 1986; 67: 1148-1153
    PubMedGoogle Scholar
  • 4 Hedner U. Experiences with recombinant factor Vila in haemophiliacs. In: Biotechnology of plasma proteins Albertini A, Lenfant CL, Mannucci PM, Sixma JJ. (eds) Curr Stud Hematol Blood Transf. Basel: Karger; 1991: 63-68
  • 5 Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J. et al Clinical experience with recombinant factor Vila in patients with thrombocytopenia. Haemostasis 1996; (Suppl. 01) 26 Suppl 159-165
    PubMedGoogle Scholar
  • 6 Ciavarella N, Schiavoni M, Valenzano E, Mangini F, Inchingolo F. Use of recombinant factor Vila (NovoSeven) in the treatment of two patients affected by type III von Willebrand’s disease with inhibitor undergoing oral surgery. Haemost 1996; 26 Suppl (Suppl. 01) 150-155
    PubMedGoogle Scholar